178437-75-7

Basic information

• Product Name: 2-acetoxy-2-(2-chlorophenyl)acetic acid
• Synonyms: 2-acetoxy-2-(2-chlorophenyl)acetic acid
• CAS NO: 178437-75-7
• Molecular Weight: 228.632
• Mol File: 178437-75-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-acetoxy-2-(2-chlorophenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-acetoxy-2-(2-chlorophenyl)acetic acid(178437-75-7)
• EPA Substance Registry System: 2-acetoxy-2-(2-chlorophenyl)acetic acid(178437-75-7)

Safety Data

• Hazardous Substances Data: 178437-75-7(Hazardous Substances Data)

Upstream product

• 10421-85-9 2-chloromandelic acid 
• 108-24-7 acetic anhydride 
• 13312-84-0 2-chloromandelonitrile 

Downstream Products

• 10421-85-9 (R)-2-chloromandelic acid 
• 1575770-33-0 C₁₀H₈ClO₄^(1-)*Na⁽¹⁺⁾ 
• 1226972-37-7 (2R)-acetoxy-2-(2-chlorophenyl)acetic acid 
• 10421-85-9 (S)-2-chloromandelic acid 
• 2444-36-2 2'-chloro-benzeneacetic acid 

Relevant articles and documents

An efficient enzymatic aminolysis for kinetic resolution of aromatic α-hydroxyl acid in non-aqueous media

A new and highly efficient enzymatic aminolysis approach for kinetic resolution of aromatic α-hydroxy acid in non-aqueous media has been developed. The corresponding α-hydroxyl acid ester was employed as the substrate, and commercially available Candida antarctica lipase B is used as the biocatalyst, anhydrous ammonia is the resolving agent. Reactions can be proceeded smoothly in organic solvent at ambient temperatures. High concentration of substrate is allowed due to the application of organic media and the products are obtained in yields of up to 49% with ee values of up to 99%, and with E value of >300, representing an appealing and promising protocol for large-scale preparations.

PERK INHIBITING PYRROLOPYRIMIDINE COMPOUNDS

Provided herein are compounds of formula (I), compositions, and methods useful for inhibiting PERK and for treating related conditions diseases, and disorders.

PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS

Provided herein are methods for treating a viral infection in a patient, comprising administering to said patient a therapeutically effective amount of a PERK inhibitor selected from a compound having the structure (I).